Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec Plans Multiple Sclerosis Portfolio Expansion

This article was originally published in The Pink Sheet Daily

Executive Summary

Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.

You may also be interested in...



Genzyme Initiates Campath Phase III Study In Multiple Sclerosis

Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.

Genzyme Initiates Campath Phase III Study In Multiple Sclerosis

Firm and partner Bayer are on track to file alemtuzumab for relapsing-remitting MS in 2011, with a launch slated for 2012.

Biogen Idec Gets Potential Oral Tysabri Follow-on In UCB Deal

The company's second oral multiple sclerosis candidate employs the same mechanism as Tysabri and is set to enter Phase II early next year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel